Suneel Kamath, MD: [00:00:00] So this this trial that the tech 24 trial was really looking at a pan G. I. Population evaluating tucatinib plus trastuzumab and then full fax chemotherapy across a number of different G. I. Cancer. The thing that was really the strength of it is that this is recognizing really that … Continue reading SGNTUC-024 Phase 1b/2 study: Tucatinib, trastuzumab, FOLFOX for HER2+ GI cancers